Cargando…

Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes

OBJECTIVE: Complete prevention of diabetic neuropathies has not been previously demonstrated. We sought to determine whether long-term near-normoglycaemia maintained from the diagnosis of type 1 diabetes is associated with polyneuropathy and cardiac autonomic dysfunction. DESIGN: Prospective observa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziegler, Dan, Behler, Margarete, Schroers-Teuber, Maria, Roden, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479996/
https://www.ncbi.nlm.nih.gov/pubmed/26109108
http://dx.doi.org/10.1136/bmjopen-2014-006559
_version_ 1782378103010492416
author Ziegler, Dan
Behler, Margarete
Schroers-Teuber, Maria
Roden, Michael
author_facet Ziegler, Dan
Behler, Margarete
Schroers-Teuber, Maria
Roden, Michael
author_sort Ziegler, Dan
collection PubMed
description OBJECTIVE: Complete prevention of diabetic neuropathies has not been previously demonstrated. We sought to determine whether long-term near-normoglycaemia maintained from the diagnosis of type 1 diabetes is associated with polyneuropathy and cardiac autonomic dysfunction. DESIGN: Prospective observational study over 24 years. SETTING: Ambulatory care. PARTICIPANTS: 32 newly diagnosed patients with type 1 diabetes aged 20.3±1.0 years, duration of diabetes 2.7±0.3 weeks. INTERVENTION: Insulin therapy according to standards of care. PRIMARY AND SECONDARY OUTCOME MEASURES: Motor and sensory nerve conduction velocity (MNCV and SNCV), heart rate variability (HRV), and confirmed clinical polyneuropathy measured at 15 time points over 24 years and quantitative sensory testing (QST) determined over 20–22 years. RESULTS: 11 patients were well controlled over 24 years with mean glycated haemoglobin (HbA1c) <7.0% (6.5±0.1%; group 1), whereas 21 patients were poorly controlled (mean HbA1c ≥7.0%: 8.3±0.2%; group 2). After 24 years, MNCV was faster in group 1 versus group 2 in the median (55.5±1.6 vs 48.9±1.6 m/s), ulnar (56.5±1.5 vs 49.3±1.7 m/s) and peroneal nerve (44.7±1.6 vs 36.8±2.5 m/s), while SNCV was faster in the median (53.6±1.6 vs 45.5±2.8 m/s), ulnar (54.7±1.8 vs 43.0±3.9 m/s), and sural nerve (44.5±1.8 vs 35.5±2.6 m/s; all p<0.05). The annual decline in peroneal MNCV and sural SNCV in group 1 was sixfold and threefold faster in group 2 than in group 1, respectively. Likewise, impairment in QST and HRV developed at faster rates in group 2. After 24 years, 64% of patients in group 2, but none in group 1, developed confirmed clinical polyneuropathy. CONCLUSIONS: Near-normoglycaemia maintained from the diagnosis of type 1 diabetes over 24 years was associated with a complete prevention of the decline in hyperglycaemia-related peripheral and autonomic nerve function, and development of confirmed clinical polyneuropathy.
format Online
Article
Text
id pubmed-4479996
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44799962015-07-02 Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes Ziegler, Dan Behler, Margarete Schroers-Teuber, Maria Roden, Michael BMJ Open Diabetes and Endocrinology OBJECTIVE: Complete prevention of diabetic neuropathies has not been previously demonstrated. We sought to determine whether long-term near-normoglycaemia maintained from the diagnosis of type 1 diabetes is associated with polyneuropathy and cardiac autonomic dysfunction. DESIGN: Prospective observational study over 24 years. SETTING: Ambulatory care. PARTICIPANTS: 32 newly diagnosed patients with type 1 diabetes aged 20.3±1.0 years, duration of diabetes 2.7±0.3 weeks. INTERVENTION: Insulin therapy according to standards of care. PRIMARY AND SECONDARY OUTCOME MEASURES: Motor and sensory nerve conduction velocity (MNCV and SNCV), heart rate variability (HRV), and confirmed clinical polyneuropathy measured at 15 time points over 24 years and quantitative sensory testing (QST) determined over 20–22 years. RESULTS: 11 patients were well controlled over 24 years with mean glycated haemoglobin (HbA1c) <7.0% (6.5±0.1%; group 1), whereas 21 patients were poorly controlled (mean HbA1c ≥7.0%: 8.3±0.2%; group 2). After 24 years, MNCV was faster in group 1 versus group 2 in the median (55.5±1.6 vs 48.9±1.6 m/s), ulnar (56.5±1.5 vs 49.3±1.7 m/s) and peroneal nerve (44.7±1.6 vs 36.8±2.5 m/s), while SNCV was faster in the median (53.6±1.6 vs 45.5±2.8 m/s), ulnar (54.7±1.8 vs 43.0±3.9 m/s), and sural nerve (44.5±1.8 vs 35.5±2.6 m/s; all p<0.05). The annual decline in peroneal MNCV and sural SNCV in group 1 was sixfold and threefold faster in group 2 than in group 1, respectively. Likewise, impairment in QST and HRV developed at faster rates in group 2. After 24 years, 64% of patients in group 2, but none in group 1, developed confirmed clinical polyneuropathy. CONCLUSIONS: Near-normoglycaemia maintained from the diagnosis of type 1 diabetes over 24 years was associated with a complete prevention of the decline in hyperglycaemia-related peripheral and autonomic nerve function, and development of confirmed clinical polyneuropathy. BMJ Publishing Group 2015-06-24 /pmc/articles/PMC4479996/ /pubmed/26109108 http://dx.doi.org/10.1136/bmjopen-2014-006559 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Diabetes and Endocrinology
Ziegler, Dan
Behler, Margarete
Schroers-Teuber, Maria
Roden, Michael
Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes
title Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes
title_full Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes
title_fullStr Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes
title_full_unstemmed Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes
title_short Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes
title_sort near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes
topic Diabetes and Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479996/
https://www.ncbi.nlm.nih.gov/pubmed/26109108
http://dx.doi.org/10.1136/bmjopen-2014-006559
work_keys_str_mv AT zieglerdan nearnormoglycaemiaanddevelopmentofneuropathya24yearprospectivestudyfromdiagnosisoftype1diabetes
AT behlermargarete nearnormoglycaemiaanddevelopmentofneuropathya24yearprospectivestudyfromdiagnosisoftype1diabetes
AT schroersteubermaria nearnormoglycaemiaanddevelopmentofneuropathya24yearprospectivestudyfromdiagnosisoftype1diabetes
AT rodenmichael nearnormoglycaemiaanddevelopmentofneuropathya24yearprospectivestudyfromdiagnosisoftype1diabetes